Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 3,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Overweight and Obesity
Interventions: Online handouts describing how to follow each diet for 1 week each; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions: Testing on new technology called Accelerate ID/AST system; Device
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 2,102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Opioid Use Disorder
Interventions: Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: OCT imaging; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more

Conditions: Diet Habit, Feeding Behavior, Behavior, Health
Interventions: Butyrate Feedback, Fiber Feedback; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV/AIDS, Hepatitis C, Substance Use Disorders, Opioid-use Disorder
Interventions: Information Control, HIV and HCV Testing Practice Coaching Intervention, HIV Testing Practice Coaching Intervention; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: MK-8591A, Islatravir, Doravine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Drug Pharmacokinetics in Healthy Volunteers
Interventions: DS-8500a, Rosuvastatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypercapnia
Interventions: standard of care for phase one anesthesia care, Quick Emergence Device; Other · Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Systemic Lupus Erythematosus
Interventions: GSK2586184 standard formulation, Simvastatin, Rosuvastatin, GSK2586184 new formulation; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Zelquistinel 3 mg, Zelquistinel 10 mg; Drug
Lead sponsor: Syndeio Biosciences, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Vascular Access Complication
Interventions: AccuCath IV Catheter Device, Conventional IV Catheter Device; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more

Conditions: Healthy
Interventions: Finasteride 5 mg tablets, PROSCAR® 5mg tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: GeneSearch™ Breast Lymph Node (BLN) Assay; Device
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions: Inhaled Technosphere Insulin; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Renal Cell Carcinoma (RCC)
Interventions: Intermittent Fasting, Continuous Energy Restriction (CER); Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Vulvar Cancer, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
Interventions: Intervention group triads; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Healthy
Interventions: MK-7602, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Obesity
Interventions: Wellness Coaching for Families and Kids; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 2 Years to 8 Years
Enrollment: 6,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Ulcerative Colitis
Interventions: A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention; Other · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Deflazacort and rifampin, Deflazacort and Clarithromycin; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer
Interventions: TALZENNA capsule, Talazoparib soft gel capsule; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • San Marcos, California + 12 more

Search by objective public record fields.

The Fasting and Shifted Timing (FAST) of Eating Study

Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

Measurements From Stool to Support Dietary Change

Project I Test: Implementing HIV Testing in Opioid Treatment Programs

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

Improved Patient Recovery After Anesthesia With Hypercapnia Hyperpnoea

A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184

Pharmacokinetics of Zelquistinel in Fasted or Fed State

AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Finasteride 5 mg Tablets, Non-fasting

Validation Study Using the GeneSearch BLN Assay to Test Sentinel Lymph Nodes From Patients With Breast Cancer

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance

Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors